Novo Nordisk (NYSE:NVO) is investing $4.1 billion to expand its US manufacturing, focusing on its high-demand weight-loss drugs, Ozempic and Wygovy. The investment will fund a new 1.4 million squar...

Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.

Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic...

In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*.

Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies.  The investment will fund a n...

Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal ha...

Novo Nordisk's top-two blockbuster drugs include the same active ingredient -- semaglutide. The company is testing an even higher-dose version of semaglutide, which may yield even better results.

The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight ...

Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...

Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.

European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.

Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight ...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk has been a dominant stock lately thanks to Ozempic, and to a lesser extent, Wegovy. The weight-loss market will, however, get a lot more crowded over the next 10 years.

Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.